Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. - Wikidata - wikimedia - TriplyDB

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.

http://www.wikidata.org/entity/Q50925934

about

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy Developing Combined HIV Vaccine Strategies for a Functional Cure Linking form to function: Biophysical aspects of artificial antigen presenting cell design Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination T-cell receptor gene therapy--ready to go viral?Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.Current advances in T-cell-based cancer immunotherapy Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.Functional attributes of responding T cells in HCV infection: the recent advances in engineering functional antiviral T cells.CAR T cells: driving the road from the laboratory to the clinic.The use of endogenous T cells for adoptive transfer.IL-21: a pleiotropic cytokine with potential applications in oncology.Exploiting cytokines in adoptive T-cell therapy of cancer.Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells.Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.Increases in iPS Transcription Factor (Oct4, Sox2, c-Myc, and Klf4) Gene Expression after Modified Electroconvulsive Therapy.IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing IL-21 in cancer immunotherapy: At the right place at the right time.Antigen-specific culture of memory-like CD8 T cells for adoptive immunotherapy.Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.MicroRNA regulation in human CD8+ T cell subsets--cytokine exposure alone drives miR-146a expression.CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

P2860

Q26752955-D82198E4-9D58-4886-B0BD-B6DD92A754C7 Q26998898-2DAD1AA9-3B4F-4BB1-A390-B61E4D69EF5B Q27002652-D545DE05-6105-40E8-911F-306170F2D159 Q27681832-D5938595-ECAE-4E9A-AA1C-320391229936 Q28068378-935F8BA0-556F-4935-8A39-58DF0748EBBF Q28081611-ED192426-6D3C-4EE6-BFC4-FDAFCB07DF6A Q33749635-857AF18D-F8BA-44CB-8DEA-410E728B8E75 Q33827997-2CB245EB-4A46-42A6-A879-7D57CDDD7FEA Q33874986-7839B16E-EAEA-44D6-AE71-8B04A8677A86 Q34580132-54C73987-3002-4E23-B9B2-19219810AC41 Q35102451-608CD59F-D30C-4A55-A14C-C940B0444E9C Q35215158-C9DA15D7-F9FA-4834-8070-17BD1ACDDCA0 Q35677962-93BB7E68-0E3C-4BBB-BF69-716E0F5310B9 Q37233539-A613FFB5-CBA3-4753-AF57-4EE579ABD8D1 Q37362636-07FF2A04-5E99-45EE-A9A2-53501C6145A5 Q37696129-CB79A9E2-5A62-4512-9822-6950B7695DD3 Q37713393-3FE50988-A971-4B59-9EA0-B30A08F29701 Q38129763-68286433-313C-41BC-8287-9FE50A2D122C Q38170499-6DDD3539-EF6D-41E2-A540-72A5E2E696A5 Q38170503-3CEB28EE-8C36-4247-B062-8AC6016CA817 Q38471387-368549F5-BD0F-4DE4-9E6F-E3EA8565610B Q38525044-0FBC2D3A-FE0C-44C5-9F9C-1BC3B0EED616 Q38777377-5D28178B-1063-4B5F-8107-457BEF6017B9 Q38805749-4B3C1C0B-2A5D-4DF7-BA8B-C9704723D4FB Q38880784-473F9204-09E6-47CA-8F26-8311458BBE55 Q38913549-6F8749C1-ECD0-489C-90AC-E14AC7C64471 Q39320917-238B50B3-5059-433C-B832-874BFF55DE50 Q39401736-88E78348-695C-4889-A7FE-6122C19F3887 Q40384784-CB14C4B2-9105-4243-98F9-EEB195B73978 Q40987686-A3501601-A5DE-4EF2-A35B-B3E060E8FC2E Q41977992-27C9617F-D74B-4C79-AC1F-34C060F0D1E5 Q42124330-98AFB013-4E18-41A4-8066-EC7A5325C080 Q42198836-BA3F6086-3ABB-410C-B1C3-956D024A4CEF Q42552126-C1D69E72-C6C4-4710-8E96-1394FB7B0CCB Q42974014-32838707-0672-484F-BAD8-9E1AE3F4E8EE Q45870963-54387110-D178-487B-9A8D-301D4DEBCB65 Q47561397-29C8E48B-C4DF-463C-AA0F-F1CBD42DD0BB Q49363296-69BB286A-2376-4EA0-BB06-6B3724C59026

P2860

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.

http://www.wikidata.org/entity/Q50925934

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Modulating the differentiation ...... ells using cytokine cocktails.

@en

Modulating the differentiation ...... ells using cytokine cocktails.

@nl

type

label

Modulating the differentiation ...... ells using cytokine cocktails.

@en

Modulating the differentiation ...... ells using cytokine cocktails.

@nl

prefLabel

Modulating the differentiation ...... ells using cytokine cocktails.

@en

Modulating the differentiation ...... ells using cytokine cocktails.

@nl

P1433

Q50925934-5318B34B-B713-49BE-8F42-E797BEF09CEC

P1476

Q50925934-803B750E-B3A1-439D-B2E5-27E5D75BB31A

P2093

Q50925934-2BEFED44-E450-4993-A1E7-D549120AFD84

Q50925934-5D0F054E-E70D-404F-9650-9ACEE5A88A3B

Q50925934-6B0048AE-C4F8-4E40-9F9F-8B68B5B51B64

Q50925934-6F6D1CDA-03BD-4069-82B0-FD78A19B986A

Q50925934-D77CADFE-6F6F-409D-BC5B-AC387FF7AADE

Q50925934-EDCB66A5-247B-4258-913C-D9CC56242FED

P2860

Q50925934-0270A4E7-BFD2-4073-ABC6-DFC1DB9FB48F

Q50925934-0A02B255-0D04-4DF0-9D23-9A8F4E4C11D7

Q50925934-0A9D59EF-3DC9-42C4-8FBC-02780A1157A6

Q50925934-1135C1C8-1F71-4761-91D6-1600084552C2

Q50925934-2E1C30D2-7AFA-4C29-B272-88F63F5D0CC1

Q50925934-3367742E-B325-4D04-881D-F9F50244E2B7

Q50925934-3ACC21FD-C429-4ADA-B5C9-5034274F1CC9

Q50925934-43C46C4A-BF55-42AD-AB77-620BB09E4A1A

Q50925934-49D59013-D87D-4E26-9385-4E753A41DA07

Q50925934-4B765E4C-60AA-48F3-9088-9F7F17C64E49

P2888

Q50925934-F17EAE5B-37A3-4F38-9F6C-21BEE582A6A4

P304

Q50925934-27288F94-8A91-41C8-BE52-B330609AE859

P31

Q50925934-E513569F-6810-4683-8E4B-38C1FDF9978C

P356

Q50925934-FFD8DC57-2F3B-4F9D-A49F-F0C0021F60AF

P433

Q50925934-5AD311C0-19E5-4F0F-A41D-454486F97959

P478

Q50925934-E7DEE96B-F943-42CA-9936-8A27F32CCC1B

P50

Q50925934-0806D93C-3EA8-4504-807D-B52D4FAA79F1

Q50925934-80786F3D-A81B-49BF-8349-9421645AF7FC

P577

Q50925934-3BCCA844-2EBC-4D29-9E83-07FA2B34884A

P5875

Q50925934-02317D5E-F33A-4CAD-BE44-D1CFA1886DBB

P698

Q50925934-F9FD6DE6-9D95-4030-98C7-0B71241DA9FA

P932

Q50925934-AEDF93FA-6347-4E2D-87C6-A5DE07839CF5

P356

S00262-012-1378-2

P1433

Cancer Immunology, Immunotherapy

P1476

Modulating the differentiation ...... cells using cytokine cocktails

@en

P2093

Ling Zhang

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Shicheng Yang

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Yun Ji

http://www.w3.org/2001/XMLSchema#string

Zhiya Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Cancer regression in patients after transfer of genetically engineered lymphocytes

Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells

A human memory T cell subset with stem cell-like properties

P2888

s00262-012-1378-2

P304

727-736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-012-1378-2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2012-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233838672

http://www.w3.org/2001/XMLSchema#string

P698

23207483

http://www.w3.org/2001/XMLSchema#string

P932

6354242

http://www.w3.org/2001/XMLSchema#string